A team of scientists have discovered that activation of designer neural receptors in the brain region can suppress cravings.
Dartmouth researchers conducted the study to systematically show how designer brain receptors and designer drugs work together to change how cues for food stimulate motivation. The findings, which may help scientists to fight addiction, overeating and other habitual behavior in humans, appear in the European Journal of Neuroscience
‘A region in the brain called, ventral pallidum is implicated in processing reward and also involved in sign-tracking, in which the reward is given regardless of the subject's behavior.’
In everyday life, we are bombarded with advertisements, or cues, that garner our attention and trigger us into purchasing products, or rewards. Consequently, these reward-paired cues can become attractive themselves. For example McDonald's golden arches can produce cravings for fast food even though you haven't seen the food or aren't even hungry. Scientists study this phenomenon using sign-tracking, or autoshaping, an experimental conditioning in which the reward is given regardless of the subject's behavior.
"Although we have a sense of what brain circuits mediate reward, less is known about the neural circuitry underlying the transfer of value to cues associated with rewards," says lead author Stephen Chang, a postdoctoral fellow. "We were primarily interested in whether the ventral pallidum, a brain region implicated in processing reward, is also involved in sign-tracking."
Previously, it was impossible to inactivate brain areas like this repeatedly and temporarily to study how cues become valuable in themselves. But it is now possible with a new technology called DREADDs (designer receptors exclusively activated by designer drugs). Your brain cells are loaded with natural receptors, or molecules like jigsaw puzzles that are activated when another molecule arrives that fits like a missing piece. But DREADDs are engineered receptors introduced into neurons using viruses. Injection of a synthetic drug can activate these receptors, thus shutting down the neurons as a sort of remote control.
This technology allowed the Dartmouth researchers to inactivate the ventral pallidum repeatedly and temporarily during tests in which a lever was inserted into the experimental chamber for 10 seconds, followed by a food pellet reward when the lever was withdrawn. Even though the food was delivered regardless of the rats' behavior, the rats pressed and bit the lever as if it were the reward itself. The results showed that activating DREADDs in the ventral pallidum before each training session blocked that behavior. In addition, recordings of individual neurons in the ventral pallidum following DREADD activation showed that ventral pallidum activity can become suppressed or excited to varying speeds and amounts.
"These results are the first to show that the ventral pallidum is necessary for the attribution of value to cues that are paired with rewards," Chang says. "This is surprising because the ventral pallidum was historically considered to be just an area for expressing motivations in behavior. In terms of clinical applications, the results carry the potential for stripping away value from reward-paired cues in cases such as addiction. The ventral pallidum is a novel target for such work."